OKYO Pharma Ltd. Form 6-K Summary
Filing date: October 20, 2022. Reporting period: The filing is a current report and does not provide financial results for a specified reporting period.
Business Context
OKYO Pharma Ltd., a foreign private issuer reporting on Form 20-F, furnished a U.K. news service announcement regarding its participation in the 2022 ThinkEquity Conference in New York.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, operating expenses, or other financial metrics.
Material Changes Versus Prior Period
No financial or operational changes versus a prior comparable period are disclosed.
Outlook, Commentary, Risks, and Unusual Items
The filing text does not include management guidance, an outlook, risk disclosures, contingencies, or unusual financial items. Exhibit 99.1 is identified as the conference announcement, but its substantive contents are not included in the provided filing text.
The information in Exhibit 99.1 was furnished and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings except where expressly stated.
Key Facts for Investors to Verify
- Review Exhibit 99.1 for the details of OKYO Pharma’s presentation and any statements made at the 2022 ThinkEquity Conference.
- Verify whether the conference announcement included pipeline, clinical, financing, or corporate development updates.
- Consult the company’s latest Form 20-F and subsequent filings for financial condition, liquidity, funding needs, and risk factors.